ArticleRheumatology advances in practice2026
Albuminuria in Lupus Nephritis: the hidden threat to cardiovascular health.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Systemic lupus erythematosus often leads to cardiovascular and renal complications, particularly in patients with lupus nephritis. In clinical practice, renal treatment response is commonly assessed using the Complete Renal Response criteria defined by the Consensus document of the Spanish Group for the Study of the Glomerular Diseases. These criteria, however, rely predominantly on proteinuria while albuminuria is often overlooked. The primary objective of our study was to assess the prevalence of pathological albuminuria in patients who met Complete Renal Response criteria. Secondary objectives included evaluating whether residual albuminuria identifies patients with different clinical outcomes. Methods: This single-centre, ambispective, observational study included 91 LN patients. Pathological albuminuria was defined as urinary albumin-creatinine ratio > 30 mg/g. Outcomes were compared between patients with and without pathological albuminuria despite achieving Complete Renal Response. Results: Among patients who met Complete Renal Response criteria, 80.5% had pathological albuminuria at the time of remission, and 55.8% continued to show it at the end of follow-up. Notably, patients with pathological albuminuria at the time of remission had significantly higher proteinuria levels both at disease onset and remission. Furthermore, persistent pathological albuminuria at follow-up was associated with more intensive antiproteinuric treatment. This therapeutic approach led to a significant reduction in both proteinuria and albuminuria titers. Conclusion: Pathological albuminuria remains common in lupus nephritis patients who meet Complete Renal Response criteria. Although cardiovascular events were infrequent during follow-up, the presence of persistent pathological albuminuria in patients meeting Complete Renal Response criteria underscores the need for close monitoring and therapeutic optimization, given its well-established association with adverse renal and cardiovascular outcomes in other glomerular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.